B-y Ryoo
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma.
Journal: ESMO open
Published: November 04, 2024
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis.
Journal: ESMO open
Published: July 13, 2022
Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX.
Journal: ESMO open
Published: February 21, 2022
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 07, 2019
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 17, 2018
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 14, 2018
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS).
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 17, 2015
Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 24, 2014
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.
Journal: British journal of cancer
Published: June 10, 2013
Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum.
Journal: British journal of cancer
Published: February 21, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026